1
|
D’Andrea G, Deroma G, Miluzio A, Biffo S. The Paradox of Ribosomal Insufficiency Coupled with Increased Cancer: Shifting the Perspective from the Cancer Cell to the Microenvironment. Cancers (Basel) 2024; 16:2392. [PMID: 39001453 PMCID: PMC11240629 DOI: 10.3390/cancers16132392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2024] [Revised: 06/25/2024] [Accepted: 06/26/2024] [Indexed: 07/16/2024] Open
Abstract
Ribosomopathies are defined as inherited diseases in which ribosomal factors are mutated. In general, they present multiorgan symptoms. In spite of the fact that in cellular models, ribosomal insufficiency leads to a reduced rate of oncogenic transformation, patients affected by ribosomopathies present a paradoxical increase in cancer incidence. Several hypotheses that explain this paradox have been formulated, mostly on the assumption that altered ribosomes in a stem cell induce compensatory changes that lead to a cancer cell. For instance, the lack of a specific ribosomal protein can lead to the generation of an abnormal ribosome, an oncoribosome, that itself leads to altered translation and increased tumorigenesis. Alternatively, the presence of ribosomal stress may induce compensatory proliferation that in turns selects the loss of tumor suppressors such as p53. However, modern views on cancer have shifted the focus from the cancer cell to the tumor microenvironment. In particular, it is evident that human lymphocytes are able to eliminate mutant cells and contribute to the maintenance of cancer-free tissues. Indeed, many tumors develop in conditions of reduced immune surveillance. In this review, we summarize the current evidence and attempt to explain cancer and ribosomopathies from the perspective of the microenvironment.
Collapse
Affiliation(s)
- Giacomo D’Andrea
- National Institute of Molecular Genetics, INGM Fondazione Romeo ed Enrica Invernizzi, 20122 Milan, Italy; (G.D.); (G.D.); (A.M.)
- Department of Biosciences, University of Milan, 20133 Milan, Italy
| | - Giorgia Deroma
- National Institute of Molecular Genetics, INGM Fondazione Romeo ed Enrica Invernizzi, 20122 Milan, Italy; (G.D.); (G.D.); (A.M.)
- Department of Biosciences, University of Milan, 20133 Milan, Italy
| | - Annarita Miluzio
- National Institute of Molecular Genetics, INGM Fondazione Romeo ed Enrica Invernizzi, 20122 Milan, Italy; (G.D.); (G.D.); (A.M.)
| | - Stefano Biffo
- National Institute of Molecular Genetics, INGM Fondazione Romeo ed Enrica Invernizzi, 20122 Milan, Italy; (G.D.); (G.D.); (A.M.)
- Department of Biosciences, University of Milan, 20133 Milan, Italy
| |
Collapse
|
2
|
Wilson RB, Kozlov AM, Hatam Tehrani H, Twumasi-Ankrah JS, Chen YJ, Borrelli MJ, Sawyez CG, Maini S, Shepherd TG, Cumming RC, Betts DH, Borradaile NM. Elongation factor 1A1 regulates metabolic substrate preference in mammalian cells. J Biol Chem 2024; 300:105684. [PMID: 38272231 PMCID: PMC10891338 DOI: 10.1016/j.jbc.2024.105684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Revised: 12/28/2023] [Accepted: 01/09/2024] [Indexed: 01/27/2024] Open
Abstract
Eukaryotic elongation factor 1A1 (EEF1A1) is canonically involved in protein synthesis but also has noncanonical functions in diverse cellular processes. Previously, we identified EEF1A1 as a mediator of lipotoxicity and demonstrated that chemical inhibition of EEF1A1 activity reduced mouse liver lipid accumulation. These findings suggested a link between EEF1A1 and metabolism. Therefore, we investigated its role in regulating metabolic substrate preference. EEF1A1-deficient Chinese hamster ovary (2E2) cells displayed reduced media lactate accumulation. These effects were also observed with EEF1A1 knockdown in human hepatocyte-like HepG2 cells and in WT Chinese hamster ovary and HepG2 cells treated with selective EEF1A inhibitors, didemnin B, or plitidepsin. Extracellular flux analyses revealed decreased glycolytic ATP production and increased mitochondrial-to-glycolytic ATP production ratio in 2E2 cells, suggesting a more oxidative metabolic phenotype. Correspondingly, fatty acid oxidation was increased in 2E2 cells. Both 2E2 cells and HepG2 cells treated with didemnin B exhibited increased neutral lipid content, which may be required to support elevated oxidative metabolism. RNA-seq revealed a >90-fold downregulation of a rate-limiting glycolytic enzyme, hexokinase 2, which we confirmed through immunoblotting and enzyme activity assays. Pathway enrichment analysis identified downregulations in TNFA signaling via NFKB and MYC targets. Correspondingly, nuclear abundances of RELB and MYC were reduced in 2E2 cells. Thus, EEF1A1 deficiency may perturb glycolysis by limiting NFKB- and MYC-mediated gene expression, leading to decreased hexokinase expression and activity. This is the first evidence of a role for a translation elongation factor, EEF1A1, in regulating metabolic substrate utilization in mammalian cells.
Collapse
Affiliation(s)
- Rachel B Wilson
- Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
| | | | - Helia Hatam Tehrani
- Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
| | - Jessica S Twumasi-Ankrah
- Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
| | - Yun Jin Chen
- Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
| | - Matthew J Borrelli
- The Mary & John Knight Translational Ovarian Cancer Research Unit, London Regional Cancer Program, London, Ontario, Canada; Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
| | - Cynthia G Sawyez
- Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
| | - Siddhant Maini
- Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
| | - Trevor G Shepherd
- The Mary & John Knight Translational Ovarian Cancer Research Unit, London Regional Cancer Program, London, Ontario, Canada; Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Department of Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Department of Obstetrics and Gynaecology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
| | - Robert C Cumming
- Department of Biology, Western University, London, Ontario, Canada; Genetics and Development Division, The Children's Health Research Institute, Lawson Health Research Institute, London, Ontario, Canada
| | - Dean H Betts
- Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Department of Biology, Western University, London, Ontario, Canada; Department of Obstetrics and Gynaecology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Genetics and Development Division, The Children's Health Research Institute, Lawson Health Research Institute, London, Ontario, Canada
| | - Nica M Borradaile
- Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
| |
Collapse
|
3
|
Mancino M, Lai G, De Grossi F, Cuomo A, Manganaro L, Butta GM, Ferrari I, Vicenzi E, Poli G, Pesce E, Oliveto S, Biffo S, Manfrini N. FAM46C Is an Interferon-Stimulated Gene That Inhibits Lentiviral Particle Production by Modulating Autophagy. Microbiol Spectr 2023; 11:e0521122. [PMID: 37358411 PMCID: PMC10434054 DOI: 10.1128/spectrum.05211-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Accepted: 06/02/2023] [Indexed: 06/27/2023] Open
Abstract
FAM46C is a multiple myeloma (MM) tumor suppressor whose function is only starting to be elucidated. We recently showed that in MM cells FAM46C triggers apoptosis by inhibiting autophagy and altering intracellular trafficking and protein secretion. To date, both a physiological characterization of FAM46C role and an assessment of FAM46C-induced phenotypes outside of MM are lacking. Preliminary reports suggested an involvement of FAM46C with regulation of viral replication, but this was never confirmed. Here, we show that FAM46C is an interferon-stimulated gene and that the expression of wild-type FAM46C in HEK-293T cells, but not of its most frequently found mutant variants, inhibits the production of both HIV-1-derived and HIV-1 lentiviruses. We demonstrate that this effect does not require transcriptional regulation and does not depend on inhibition of either global or virus-specific translation but rather mostly relies on FAM46C-induced deregulation of autophagy, a pathway that we show to be required for efficient lentiviral particle production. These studies not only provide new insights on the physiological role of the FAM46C protein but also could help in implementing more efficient antiviral strategies on one side and lentiviral particle production approaches on the other. IMPORTANCE FAM46C role has been thoroughly investigated in MM, but studies characterizing its role outside of the tumoral environment are still lacking. Despite the success of antiretroviral therapy in suppressing HIV load to undetectable levels, there is currently no HIV cure, and treatment is lifelong. Indeed, HIV continues to be a major global public health issue. Here, we show that FAM46C expression in HEK-293T cells inhibits the production of both HIV and HIV-derived lentiviruses. We also demonstrate that such inhibitory effect relies, at least in part, on the well-established regulatory role that FAM46C exerts on autophagy. Deciphering the molecular mechanism underlying this regulation will not only facilitate the understanding of FAM46C physiological role but also give new insights on the interplay between HIV and the cellular environment.
Collapse
Affiliation(s)
- Marilena Mancino
- INGM, Istituto Nazionale Genetica Molecolare Romeo ed Enrica Invernizzi, Milan, Italy
| | - Giancarlo Lai
- INGM, Istituto Nazionale Genetica Molecolare Romeo ed Enrica Invernizzi, Milan, Italy
| | | | - Alessandro Cuomo
- Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - Lara Manganaro
- INGM, Istituto Nazionale Genetica Molecolare Romeo ed Enrica Invernizzi, Milan, Italy
- Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
| | - Giacomo M. Butta
- INGM, Istituto Nazionale Genetica Molecolare Romeo ed Enrica Invernizzi, Milan, Italy
- Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
| | - Ivan Ferrari
- INGM, Istituto Nazionale Genetica Molecolare Romeo ed Enrica Invernizzi, Milan, Italy
| | - Elisa Vicenzi
- Viral Pathogenesis and Biosafety Unit, San Raffaele Scientific Institute, Milan, Italy
| | - Guido Poli
- Viral Pathogenesis and Biosafety Unit, San Raffaele Scientific Institute, Milan, Italy
- Vita-Salute San Raffaele University School of Medicine, Milan, Italy
| | - Elisa Pesce
- INGM, Istituto Nazionale Genetica Molecolare Romeo ed Enrica Invernizzi, Milan, Italy
| | - Stefania Oliveto
- INGM, Istituto Nazionale Genetica Molecolare Romeo ed Enrica Invernizzi, Milan, Italy
- Department of Biosciences, University of Milan, Milan, Italy
| | - Stefano Biffo
- INGM, Istituto Nazionale Genetica Molecolare Romeo ed Enrica Invernizzi, Milan, Italy
- Department of Biosciences, University of Milan, Milan, Italy
| | - Nicola Manfrini
- INGM, Istituto Nazionale Genetica Molecolare Romeo ed Enrica Invernizzi, Milan, Italy
- Department of Biosciences, University of Milan, Milan, Italy
| |
Collapse
|
4
|
Miluzio A, Cuomo A, Cordiglieri C, Donnici L, Pesce E, Bombaci M, Conti M, Fasciani A, Terracciano L, Manganaro L, Toccafondi M, Scagliola A, Oliveto S, Ricciardi S, Grifantini R, De Francesco R, Abrignani S, Manfrini N, Biffo S. Mapping of functional SARS-CoV-2 receptors in human lungs establishes differences in variant binding and SLC1A5 as a viral entry modulator of hACE2. EBioMedicine 2022; 87:104390. [PMID: 36584595 PMCID: PMC9795807 DOI: 10.1016/j.ebiom.2022.104390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 11/15/2022] [Accepted: 11/17/2022] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND The COVID-19 pandemic is an infectious disease caused by SARS-CoV-2. The first step of SARS-CoV-2 infection is the recognition of angiotensin-converting enzyme 2 (ACE2) receptors by the receptor-binding domain (RBD) of the viral Spike (S) glycoprotein. Although the molecular and structural bases of the SARS-CoV-2-RBD/hACE2 interaction have been thoroughly investigated in vitro, the relationship between hACE2 expression and in vivo infection is less understood. METHODS Here, we developed an efficient SARS-CoV-2-RBD binding assay suitable for super resolution microscopy and simultaneous hACE2 immunodetection and mapped the correlation between hACE2 receptor abundance and SARS-CoV-2-RBD binding, both in vitro and in human lung biopsies. Next, we explored the specific proteome of SARS-CoV-2-RBD/hACE2 through a comparative mass spectrometry approach. FINDINGS We found that only a minority of hACE2 positive spots are actually SARS-CoV-2-RBD binding sites, and that the relationship between SARS-CoV-2-RBD binding and hACE2 presence is variable, suggesting the existence of additional factors. Indeed, we found several interactors that are involved in receptor localization and viral entry and characterized one of them: SLC1A5, an amino acid transporter. High-resolution receptor-binding studies showed that co-expression of membrane-bound SLC1A5 with hACE2 predicted SARS-CoV-2 binding and entry better than hACE2 expression alone. SLC1A5 depletion reduces SARS-CoV-2 binding and entry. Notably, the Omicron variant is more efficient in binding hACE2 sites, but equally sensitive to SLC1A5 downregulation. INTERPRETATION We propose a method for mapping functional SARS-CoV-2 receptors in vivo. We confirm the existence of hACE2 co-factors that may contribute to differential sensitivity of cells to infection. FUNDING This work was supported by an unrestricted grant from "Fondazione Romeo ed Enrica Invernizzi" to Stefano Biffo and by AIRC under MFAG 2021 - ID. 26178 project - P.I. Manfrini Nicola.
Collapse
Affiliation(s)
- Annarita Miluzio
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy
| | - Alessandro Cuomo
- Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20141, Milan, Italy
| | - Chiara Cordiglieri
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy
| | - Lorena Donnici
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy
| | - Elisa Pesce
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy
| | - Mauro Bombaci
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy
| | - Matteo Conti
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy
| | - Alessandra Fasciani
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy
| | - Luigi Terracciano
- Institute of Pathology, University Hospital Basel, 4031, Basel, Switzerland
| | - Lara Manganaro
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy
| | - Mirco Toccafondi
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy
| | - Alessandra Scagliola
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy
| | - Stefania Oliveto
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy
| | - Sara Ricciardi
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy,Department of Biosciences, University of Milan, 20133, Milan, Italy
| | - Renata Grifantini
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy
| | - Raffaele De Francesco
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy,Department of Pharmacological and Biomolecular Sciences, University of Milan, 20133, Milan, Italy
| | - Sergio Abrignani
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy,Department of Clinical Sciences and Community Health, University of Milan, 20122, Milan, Italy
| | - Nicola Manfrini
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy,Department of Biosciences, University of Milan, 20133, Milan, Italy,Corresponding author. National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy.
| | - Stefano Biffo
- National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy,Department of Biosciences, University of Milan, 20133, Milan, Italy,Corresponding author. National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", INGM, 20122, Milan, Italy.
| |
Collapse
|
5
|
Chen Y, Wang Z, Xian X, Zhuang Y, Chang J, Zhan X, Han X, Chen Q, Yang Z, Chen R. Eukaryotic initiation factor 6 repression mitigates atherosclerosis progression by inhibiting macrophages expressing Fasn. IUBMB Life 2022; 75:440-452. [PMID: 36469534 DOI: 10.1002/iub.2696] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2022] [Accepted: 11/09/2022] [Indexed: 12/12/2022]
Abstract
Atherosclerosis, a chronic inflammatory disease that often leads to myocardial infarction and stroke, is mainly caused by lipid accumulation. Eukaryotic initiation factor 6 (Eif6) is a rate-limiting factor in protein translation of transcription factors necessary for lipogenesis. To determine whether Eif6 affects atherosclerosis, Eif6+/- mice were crossed into Apoe-/- background. Apoe-/-/Eif6+/- mice on high fat diet showed significant reduction in atherosclerotic lesions and necrotic core content in aortic root sections in comparison with Apoe-/- mice. RNA-Seq was used to investigate the effect of Eif6 in aorta. Deficiency of Eif6 shows broad effect on cell metabolism. Expression of genes for fatty acid synthesis including Fatty acid synthase (Fasn), Elovl3, Elovl6 and Acaca are down-regulated in aortas. Importantly, Fasn is decreased in macrophages. Results suggest that Eif6 deficiency may decrease atherosclerosis through inhibition of Fasn and lipids metabolism in macrophages.
Collapse
Affiliation(s)
- Yang Chen
- College of Life Sciences Xuzhou Medical University Xuzhou China
| | - Zhenzhen Wang
- Cancer Institute Xuzhou Medical University Xuzhou China
| | - Xuemei Xian
- College of Life Sciences Xuzhou Medical University Xuzhou China
| | - Yun Zhuang
- College of Life Sciences Xuzhou Medical University Xuzhou China
| | - Jiajia Chang
- College of Life Sciences Xuzhou Medical University Xuzhou China
| | - Xiaoqiang Zhan
- College of Life Sciences Xuzhou Medical University Xuzhou China
| | - Xufeng Han
- College of Life Sciences Xuzhou Medical University Xuzhou China
| | - Quangang Chen
- College of Life Sciences Xuzhou Medical University Xuzhou China
| | - Zhangping Yang
- Jiangsu Key Laboratory of Animal genetic Breeding and Molecular Design Yangzhou University Yangzhou China
| | - Renjin Chen
- College of Life Sciences Xuzhou Medical University Xuzhou China
| |
Collapse
|
6
|
Zhang F, Waheed S, Armato U, Wu J, Zhang C, Li Z. eIF6 as a Promising Diagnostic and Prognostic Biomarker for Poorer Survival of Cutaneous Melanoma. Front Oncol 2022; 12:848346. [PMID: 35707354 PMCID: PMC9189357 DOI: 10.3389/fonc.2022.848346] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Accepted: 04/25/2022] [Indexed: 11/16/2022] Open
Abstract
Background Skin cutaneous melanoma (SKCM) is the deadliest skin cancer and has the most rapidly increasing incidences among all cancer types. Previous research elucidated that melanoma can only be successfully treated with surgical abscission in the early stage. Therefore, reliable and specific biomarkers are crucial to melanoma diagnosis since it often looks like nevi in the clinical manifestations. Moreover, identifying key genes contributing to melanoma progression is also highly regarded as a potential strategy for melanoma therapy. In this respect, translation initiator eIF6 has been proved as a pro-tumor factor in several cancers. However, the role of eIF6 in the skin cutaneous melanoma progression and its potential as a prognostic marker is still unexplored. Methods The immunochemical analysis of clinical specimens were served to assess eIF6 expression levels. Gene Expression Profiling Interactive Analysis (GEPIA) database consultations allowed us to find the survival rates of the eIF6-overexpressed patients. eIF6 cellular effects were evaluated in an eIF6-overexpressed A375 cell line constructed with a lentivirus. The analysis of down-stream effectors or pathways was conducted using C-Bioportal and STRING databases. Results Our results revealed that eIF6 was highly over-expressed in melanomas compared to normal skin specimens, and thus the abnormally high level of eIF6 can be a diagnostic marker for melanoma. The in silica analysis indicated that patients with eIF6 over-expression had lower survival rates than that low-expression in SKCM. Meanwhile, similar results also could be found in the other four types of cancers. In vitro, over-expression of eIF6 increased the proliferation and migration of melanoma cells. Correspondingly, pan-cancer clustering analysis indicated the expression level of intermediate filament proteins was correlated with that of eIF6 expression. In our study, all over-expressed keratin proteins, in accordance with over-expressed eIF6, had a negative correlation with melanoma prognosis. Moreover, the decreased methylation level of keratin genes suggested a new potential regulation mode of eIF6. Conclusions The up-regulated eIF6 could be a potential diagnostic and prognostic biomarker of melanoma. This study also provides insights into the potential role of eIF6 in pan-cancer epigenetic regulation.
Collapse
Affiliation(s)
- Fangyingnan Zhang
- School of Biomedical Engineering, Sun Yat-sen University, Guangzhou, China
- Department of Burn and Plastic Surgery, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
| | - Saquib Waheed
- Department of Burn and Plastic Surgery, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
| | - Ubaldo Armato
- Department of Burn and Plastic Surgery, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
| | - Jun Wu
- School of Biomedical Engineering, Sun Yat-sen University, Guangzhou, China
- Department of Burn and Plastic Surgery, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
| | - Chao Zhang
- School of Biomedical Engineering, Sun Yat-sen University, Guangzhou, China
- *Correspondence: Zhibin Li, ; Chao Zhang,
| | - Zhibin Li
- Department of Burn and Plastic Surgery, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, China
- *Correspondence: Zhibin Li, ; Chao Zhang,
| |
Collapse
|
7
|
De Silva D, Ferguson L, Chin GH, Smith BE, Apathy RA, Roth TL, Blaeschke F, Kudla M, Marson A, Ingolia NT, Cate JHD. Robust T cell activation requires an eIF3-driven burst in T cell receptor translation. eLife 2021; 10:e74272. [PMID: 34970966 PMCID: PMC8758144 DOI: 10.7554/elife.74272] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Accepted: 12/30/2021] [Indexed: 11/13/2022] Open
Abstract
Activation of T cells requires a rapid surge in cellular protein synthesis. However, the role of translation initiation in the early induction of specific genes remains unclear. Here, we show human translation initiation factor eIF3 interacts with select immune system related mRNAs including those encoding the T cell receptor (TCR) subunits TCRA and TCRB. Binding of eIF3 to the TCRA and TCRB mRNA 3'-untranslated regions (3'-UTRs) depends on CD28 coreceptor signaling and regulates a burst in TCR translation required for robust T cell activation. Use of the TCRA or TCRB 3'-UTRs to control expression of an anti-CD19 chimeric antigen receptor (CAR) improves the ability of CAR-T cells to kill tumor cells in vitro. These results identify a new mechanism of eIF3-mediated translation control that can aid T cell engineering for immunotherapy applications.
Collapse
Affiliation(s)
- Dasmanthie De Silva
- Department of Molecular and Cell Biology, University of California-BerkeleyBerkeleyUnited States
- The J. David Gladstone InstitutesSan FranciscoUnited States
| | - Lucas Ferguson
- Department of Molecular and Cell Biology, University of California-BerkeleyBerkeleyUnited States
| | - Grant H Chin
- Department of Molecular and Cell Biology, University of California-BerkeleyBerkeleyUnited States
| | - Benjamin E Smith
- School of Optometry, University of California, BerkeleyBerkeleyUnited States
| | - Ryan A Apathy
- Department of Microbiology and Immunology, University of California, San FranciscoSan FranciscoUnited States
| | - Theodore L Roth
- Department of Microbiology and Immunology, University of California, San FranciscoSan FranciscoUnited States
| | | | - Marek Kudla
- Department of Molecular and Cell Biology, University of California-BerkeleyBerkeleyUnited States
| | - Alexander Marson
- Department of Microbiology and Immunology, University of California, San FranciscoSan FranciscoUnited States
- Gladstone-UCSF Institute of Genomic ImmunologySan FranciscoUnited States
- Diabetes Center, University of California, San FranciscoSan FranciscoUnited States
- Chan Zuckerberg BiohubSan FranciscoUnited States
- Department of Medicine, University of California, San FranciscoSan FranciscoUnited States
- Parker Institute for Cancer ImmunotherapySan FranciscoUnited States
- Innovative Genomics Institute, University of California, BerkeleyBerkeleyUnited States
| | - Nicholas T Ingolia
- Department of Molecular and Cell Biology, University of California-BerkeleyBerkeleyUnited States
- California Institute for Quantitative Biosciences, University of California, BerkeleyBerkeleyUnited States
| | - Jamie HD Cate
- Department of Molecular and Cell Biology, University of California-BerkeleyBerkeleyUnited States
- The J. David Gladstone InstitutesSan FranciscoUnited States
- Innovative Genomics Institute, University of California, BerkeleyBerkeleyUnited States
- California Institute for Quantitative Biosciences, University of California, BerkeleyBerkeleyUnited States
- Department of Chemistry, University of California-BerkeleyBerkeleyUnited States
- Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National LaboratoryBerkeleyUnited States
| |
Collapse
|
8
|
Scagliola A, Miluzio A, Ventura G, Oliveto S, Cordiglieri C, Manfrini N, Cirino D, Ricciardi S, Valenti L, Baselli G, D'Ambrosio R, Maggioni M, Brina D, Bresciani A, Biffo S. Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma. Nat Commun 2021; 12:4878. [PMID: 34385447 PMCID: PMC8361022 DOI: 10.1038/s41467-021-25195-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Accepted: 07/24/2021] [Indexed: 12/30/2022] Open
Abstract
A postprandial increase of translation mediated by eukaryotic Initiation Factor 6 (eIF6) occurs in the liver. Its contribution to steatosis and disease is unknown. In this study we address whether eIF6-driven translation contributes to disease progression. eIF6 levels increase throughout the progression from Non-Alcoholic Fatty Liver Disease (NAFLD) to hepatocellular carcinoma. Reduction of eIF6 levels protects the liver from disease progression. eIF6 depletion blunts lipid accumulation, increases fatty acid oxidation (FAO) and reduces oncogenic transformation in vitro. In addition, eIF6 depletion delays the progression from NAFLD to hepatocellular carcinoma, in vivo. Mechanistically, eIF6 depletion reduces the translation of transcription factor C/EBPβ, leading to a drop in biomarkers associated with NAFLD progression to hepatocellular carcinoma and preserves mitochondrial respiration due to the maintenance of an alternative mTORC1-eIF4F translational branch that increases the expression of transcription factor YY1. We provide proof-of-concept that in vitro pharmacological inhibition of eIF6 activity recapitulates the protective effects of eIF6 depletion. We hypothesize the existence of a targetable, evolutionarily conserved translation circuit optimized for lipid accumulation and tumor progression.
Collapse
Affiliation(s)
- Alessandra Scagliola
- Istituto Nazionale di Genetica Molecolare, INGM, "Romeo ed Enrica Invernizzi", Milan, Italy
| | - Annarita Miluzio
- Istituto Nazionale di Genetica Molecolare, INGM, "Romeo ed Enrica Invernizzi", Milan, Italy
| | | | - Stefania Oliveto
- Istituto Nazionale di Genetica Molecolare, INGM, "Romeo ed Enrica Invernizzi", Milan, Italy
| | - Chiara Cordiglieri
- Istituto Nazionale di Genetica Molecolare, INGM, "Romeo ed Enrica Invernizzi", Milan, Italy
| | - Nicola Manfrini
- Istituto Nazionale di Genetica Molecolare, INGM, "Romeo ed Enrica Invernizzi", Milan, Italy
- Department of Biosciences, University of Milan, Milan, Italy
| | - Delia Cirino
- Department of Biosciences, University of Milan, Milan, Italy
| | - Sara Ricciardi
- Istituto Nazionale di Genetica Molecolare, INGM, "Romeo ed Enrica Invernizzi", Milan, Italy
- Department of Biosciences, University of Milan, Milan, Italy
| | - Luca Valenti
- Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
- Translational Medicine, Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Policlinico, Milan, Italy
| | - Guido Baselli
- Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
| | - Roberta D'Ambrosio
- Department of Hepatology, Fondazione IRCCS Ca' Granda Granda Ospedale Policlinico, Milan, Italy
| | - Marco Maggioni
- Department of Pathology, Fondazione IRCCS Ca' Granda Ospedale Policlinico, Milan, Italy
| | - Daniela Brina
- Institute of Oncology Research, Oncology Institute of Southern Switzerland, Università della Svizzera Italiana, Bellinzona, Switzerland
| | - Alberto Bresciani
- Department of Translational and Discovery Research, IRBM S.p.A., Pomezia (Roma), Italy
| | - Stefano Biffo
- Istituto Nazionale di Genetica Molecolare, INGM, "Romeo ed Enrica Invernizzi", Milan, Italy.
- Department of Biosciences, University of Milan, Milan, Italy.
| |
Collapse
|
9
|
Manfrini N, Ricciardi S, Alfieri R, Ventura G, Calamita P, Favalli A, Biffo S. Ribosome profiling unveils translational regulation of metabolic enzymes in primary CD4 + Th1 cells. DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY 2020; 109:103697. [PMID: 32330465 DOI: 10.1016/j.dci.2020.103697] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Revised: 04/06/2020] [Accepted: 04/06/2020] [Indexed: 05/22/2023]
Abstract
The transition from a naïve to an effector T cell is an essential event that requires metabolic reprogramming. We have recently demonstrated that the rapid metabolic changes that occur following stimulation of naïve T cells require the translation of preexisting mRNAs. Here, we provide evidence that translation regulates the metabolic asset of effector T cells. By performing ribosome profiling in human CD4+ Th1 cells, we show that the metabolism of glucose, fatty acids and pentose phosphates is regulated at the translational level. In Th1 cells, each pathway has at least one enzyme regulated at the translational level and selected enzymes have high translational efficiencies. mRNA expression does not predict protein expression. For instance, PKM2 mRNA is equally present in naïve T and Th1 cells, but the protein is abundant only in Th1. 5'-untranslated regions (UTRs) may partly account for this regulation. Overall we suggest that immunometabolism is controlled by translation.
Collapse
Affiliation(s)
- Nicola Manfrini
- INGM, National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", Milano, Italy; Department of Biological Sciences, University of Milan, Milan, Italy
| | - Sara Ricciardi
- INGM, National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", Milano, Italy; Department of Biological Sciences, University of Milan, Milan, Italy
| | - Roberta Alfieri
- INGM, National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", Milano, Italy
| | - Gabriele Ventura
- Department of Biological Sciences, University of Milan, Milan, Italy
| | - Piera Calamita
- INGM, National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", Milano, Italy; Department of Biological Sciences, University of Milan, Milan, Italy
| | - Andrea Favalli
- Department of Biological Sciences, University of Milan, Milan, Italy
| | - Stefano Biffo
- INGM, National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi", Milano, Italy; Department of Biological Sciences, University of Milan, Milan, Italy.
| |
Collapse
|
10
|
Pesce E, Miluzio A, Turcano L, Minici C, Cirino D, Calamita P, Manfrini N, Oliveto S, Ricciardi S, Grifantini R, Degano M, Bresciani A, Biffo S. Discovery and Preliminary Characterization of Translational Modulators that Impair the Binding of eIF6 to 60S Ribosomal Subunits. Cells 2020; 9:cells9010172. [PMID: 31936702 PMCID: PMC7017188 DOI: 10.3390/cells9010172] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2019] [Revised: 01/07/2020] [Accepted: 01/08/2020] [Indexed: 12/14/2022] Open
Abstract
Eukaryotic initiation factor 6 (eIF6) is necessary for the nucleolar biogenesis of 60S ribosomes. However, most of eIF6 resides in the cytoplasm, where it acts as an initiation factor. eIF6 is necessary for maximal protein synthesis downstream of growth factor stimulation. eIF6 is an antiassociation factor that binds 60S subunits, in turn preventing premature 40S joining and thus the formation of inactive 80S subunits. It is widely thought that eIF6 antiassociation activity is critical for its function. Here, we exploited and improved our assay for eIF6 binding to ribosomes (iRIA) in order to screen for modulators of eIF6 binding to the 60S. Three compounds, eIFsixty-1 (clofazimine), eIFsixty-4, and eIFsixty-6 were identified and characterized. All three inhibit the binding of eIF6 to the 60S in the micromolar range. eIFsixty-4 robustly inhibits cell growth, whereas eIFsixty-1 and eIFsixty-6 might have dose- and cell-specific effects. Puromycin labeling shows that eIF6ixty-4 is a strong global translational inhibitor, whereas the other two are mild modulators. Polysome profiling and RT-qPCR show that all three inhibitors reduce the specific translation of well-known eIF6 targets. In contrast, none of them affect the nucleolar localization of eIF6. These data provide proof of principle that the generation of eIF6 translational modulators is feasible.
Collapse
Affiliation(s)
- Elisa Pesce
- National Institute of Molecular Genetics, “Fondazione Romeo ed Enrica Invernizzi”, INGM, Via Francesco Sforza 35, 20122 Milan, Italy; (E.P.); (A.M.); (D.C.); (P.C.); (N.M.); (S.O.); (S.R.); (R.G.)
| | - Annarita Miluzio
- National Institute of Molecular Genetics, “Fondazione Romeo ed Enrica Invernizzi”, INGM, Via Francesco Sforza 35, 20122 Milan, Italy; (E.P.); (A.M.); (D.C.); (P.C.); (N.M.); (S.O.); (S.R.); (R.G.)
| | - Lorenzo Turcano
- Department of Translational and Discovery Research, IRBM S.p.A., Via Pontina km 30, 600, 00071 Pomezia (Roma), Italy;
| | - Claudia Minici
- Biocrystallography Unit, Dept. of Immunology, Transplantation and Infectious Diseases, IRCCS Scientific Institute San Raffaele, Via Olgettina 58, 20132 Milan, Italy; (C.M.); (M.D.)
| | - Delia Cirino
- National Institute of Molecular Genetics, “Fondazione Romeo ed Enrica Invernizzi”, INGM, Via Francesco Sforza 35, 20122 Milan, Italy; (E.P.); (A.M.); (D.C.); (P.C.); (N.M.); (S.O.); (S.R.); (R.G.)
- DBS, University of Milan, Via Celoria 26, 20133 Milan, Italy
| | - Piera Calamita
- National Institute of Molecular Genetics, “Fondazione Romeo ed Enrica Invernizzi”, INGM, Via Francesco Sforza 35, 20122 Milan, Italy; (E.P.); (A.M.); (D.C.); (P.C.); (N.M.); (S.O.); (S.R.); (R.G.)
- DBS, University of Milan, Via Celoria 26, 20133 Milan, Italy
| | - Nicola Manfrini
- National Institute of Molecular Genetics, “Fondazione Romeo ed Enrica Invernizzi”, INGM, Via Francesco Sforza 35, 20122 Milan, Italy; (E.P.); (A.M.); (D.C.); (P.C.); (N.M.); (S.O.); (S.R.); (R.G.)
- DBS, University of Milan, Via Celoria 26, 20133 Milan, Italy
| | - Stefania Oliveto
- National Institute of Molecular Genetics, “Fondazione Romeo ed Enrica Invernizzi”, INGM, Via Francesco Sforza 35, 20122 Milan, Italy; (E.P.); (A.M.); (D.C.); (P.C.); (N.M.); (S.O.); (S.R.); (R.G.)
- DBS, University of Milan, Via Celoria 26, 20133 Milan, Italy
| | - Sara Ricciardi
- National Institute of Molecular Genetics, “Fondazione Romeo ed Enrica Invernizzi”, INGM, Via Francesco Sforza 35, 20122 Milan, Italy; (E.P.); (A.M.); (D.C.); (P.C.); (N.M.); (S.O.); (S.R.); (R.G.)
- DBS, University of Milan, Via Celoria 26, 20133 Milan, Italy
| | - Renata Grifantini
- National Institute of Molecular Genetics, “Fondazione Romeo ed Enrica Invernizzi”, INGM, Via Francesco Sforza 35, 20122 Milan, Italy; (E.P.); (A.M.); (D.C.); (P.C.); (N.M.); (S.O.); (S.R.); (R.G.)
| | - Massimo Degano
- Biocrystallography Unit, Dept. of Immunology, Transplantation and Infectious Diseases, IRCCS Scientific Institute San Raffaele, Via Olgettina 58, 20132 Milan, Italy; (C.M.); (M.D.)
| | - Alberto Bresciani
- Department of Translational and Discovery Research, IRBM S.p.A., Via Pontina km 30, 600, 00071 Pomezia (Roma), Italy;
- Correspondence: (A.B.); (S.B.)
| | - Stefano Biffo
- National Institute of Molecular Genetics, “Fondazione Romeo ed Enrica Invernizzi”, INGM, Via Francesco Sforza 35, 20122 Milan, Italy; (E.P.); (A.M.); (D.C.); (P.C.); (N.M.); (S.O.); (S.R.); (R.G.)
- DBS, University of Milan, Via Celoria 26, 20133 Milan, Italy
- Correspondence: (A.B.); (S.B.)
| |
Collapse
|
11
|
Ricciardi S, Manfrini N, Alfieri R, Calamita P, Crosti MC, Gallo S, Müller R, Pagani M, Abrignani S, Biffo S. The Translational Machinery of Human CD4 + T Cells Is Poised for Activation and Controls the Switch from Quiescence to Metabolic Remodeling. Cell Metab 2018; 28:895-906.e5. [PMID: 30197303 PMCID: PMC6773601 DOI: 10.1016/j.cmet.2018.08.009] [Citation(s) in RCA: 100] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Revised: 03/24/2018] [Accepted: 08/07/2018] [Indexed: 12/13/2022]
Abstract
Naive T cells respond to T cell receptor (TCR) activation by leaving quiescence, remodeling metabolism, initiating expansion, and differentiating toward effector T cells. The molecular mechanisms coordinating the naive to effector transition are central to the functioning of the immune system, but remain elusive. Here, we discover that T cells fulfill this transitional process through translational control. Naive cells accumulate untranslated mRNAs encoding for glycolysis and fatty acid synthesis factors and possess a translational machinery poised for immediate protein synthesis. Upon TCR engagement, activation of the translational machinery leads to synthesis of GLUT1 protein to drive glucose entry. Subsequently, translation of ACC1 mRNA completes metabolic reprogramming toward an effector phenotype. Notably, inhibition of the eIF4F complex abrogates lymphocyte metabolic activation and differentiation, suggesting ACC1 to be a key regulatory node. Thus, our results demonstrate that translation is a direct mediator of T cell metabolism and indicate translation factors as targets for novel immunotherapeutic approaches.
Collapse
Affiliation(s)
- Sara Ricciardi
- INGM, National Institute of Molecular Genetics, "Romeo ed Enrica Invernizzi", Via Francesco Sforza 35, Milan 20122, Italy; Bioscience Department, Università degli Studi di Milano, Milan, Italy
| | - Nicola Manfrini
- INGM, National Institute of Molecular Genetics, "Romeo ed Enrica Invernizzi", Via Francesco Sforza 35, Milan 20122, Italy
| | - Roberta Alfieri
- INGM, National Institute of Molecular Genetics, "Romeo ed Enrica Invernizzi", Via Francesco Sforza 35, Milan 20122, Italy
| | - Piera Calamita
- INGM, National Institute of Molecular Genetics, "Romeo ed Enrica Invernizzi", Via Francesco Sforza 35, Milan 20122, Italy; Bioscience Department, Università degli Studi di Milano, Milan, Italy
| | - Maria Cristina Crosti
- INGM, National Institute of Molecular Genetics, "Romeo ed Enrica Invernizzi", Via Francesco Sforza 35, Milan 20122, Italy
| | - Simone Gallo
- INGM, National Institute of Molecular Genetics, "Romeo ed Enrica Invernizzi", Via Francesco Sforza 35, Milan 20122, Italy
| | - Rolf Müller
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research and Department of Pharmacy, Saarland University Campus, Building C2.3, Saarbrücken 66123, Germany
| | - Massimiliano Pagani
- INGM, National Institute of Molecular Genetics, "Romeo ed Enrica Invernizzi", Via Francesco Sforza 35, Milan 20122, Italy; Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy
| | - Sergio Abrignani
- INGM, National Institute of Molecular Genetics, "Romeo ed Enrica Invernizzi", Via Francesco Sforza 35, Milan 20122, Italy; Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy
| | - Stefano Biffo
- INGM, National Institute of Molecular Genetics, "Romeo ed Enrica Invernizzi", Via Francesco Sforza 35, Milan 20122, Italy; Bioscience Department, Università degli Studi di Milano, Milan, Italy.
| |
Collapse
|
12
|
Horta AB, Ardisson-Araujo DMP, da Silva LA, de Melo FL, da Silva Morgado F, Franco Lemos MV, Ribeiro ZA, Boiça AL, Wilcken CF, Ribeiro BM. Genomic analysis of a cypovirus isolated from the eucalyptus brown looper, Thyrinteina arnobia (Stoll, 1782) (Lepidoptera: Geometridae). Virus Res 2018; 253:62-67. [DOI: 10.1016/j.virusres.2018.05.026] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2018] [Revised: 05/24/2018] [Accepted: 05/30/2018] [Indexed: 11/26/2022]
|
13
|
RNA-binding proteins control gene expression and cell fate in the immune system. Nat Immunol 2018; 19:120-129. [PMID: 29348497 DOI: 10.1038/s41590-017-0028-4] [Citation(s) in RCA: 122] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2017] [Accepted: 11/29/2017] [Indexed: 12/19/2022]
Abstract
RNA-binding proteins (RBPs) are essential for the development and function of the immune system. They interact dynamically with RNA to control its biogenesis and turnover by transcription-dependent and transcription-independent mechanisms. In this Review, we discuss the molecular mechanisms by which RBPs allow gene expression changes to occur at different speeds and to varying degrees, and which RBPs regulate the diversity of the transcriptome and proteome. These proteins are nodes for integration of transcriptional and signaling networks and are intimately linked to intermediary metabolism. They are essential components of regulatory feedback mechanisms that maintain immune tolerance and limit inflammation. The role of RBPs in malignancy and autoimmunity has led to their emergence as targets for the development of new therapeutic modalities.
Collapse
|
14
|
Romano N, Ricciardi S, Gallo P, Ceci M. Upregulation of eIF6 inhibits cardiac hypertrophy induced by phenylephrine. Biochem Biophys Res Commun 2018; 495:601-606. [DOI: 10.1016/j.bbrc.2017.11.046] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2017] [Accepted: 11/07/2017] [Indexed: 11/29/2022]
|
15
|
Biffo S, Manfrini N, Ricciardi S. Crosstalks between translation and metabolism in cancer. Curr Opin Genet Dev 2017; 48:75-81. [PMID: 29153483 DOI: 10.1016/j.gde.2017.10.011] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2017] [Revised: 10/23/2017] [Accepted: 10/24/2017] [Indexed: 12/26/2022]
Abstract
Albeit cancer patients' heterogeneity, all tumor cells have alterations of both metabolism and translation. The simplest explanation for this common feature is that several oncogenes coordinate a translational and metabolic reprogramming that is necessary for tumor cells to thrive. Overall, at least three oncogenic pathways, namely c-Myc, RAS and PI3K-mTOR, are known to affect both translation and metabolism by stimulating glycolysis and protein synthesis. The crosstalk between metabolite production and the translational machinery is, instead, less understood. What is known is that, on one side, translation initiation factors, such as eIF4E and eIF6, drive tumor growth and regulate metabolism through selective translation of nucleotide biosynthesis, glycolysis and fatty acid synthesis rate-limiting mRNAs, and on the other, that nutrient levels regulate the translational machinery by inducing full activity of translation factors. Therefore, translation and metabolism offer several therapeutic targets to be fully exploited in future studies.
Collapse
Affiliation(s)
- Stefano Biffo
- National Institute of Molecular Genetics "Romeo ed Enrica Invernizzi", INGM, 20122 Milano, Italy; Department of Biosciences, University of Milano, 20133 Milano, Italy.
| | - Nicola Manfrini
- National Institute of Molecular Genetics "Romeo ed Enrica Invernizzi", INGM, 20122 Milano, Italy
| | - Sara Ricciardi
- National Institute of Molecular Genetics "Romeo ed Enrica Invernizzi", INGM, 20122 Milano, Italy
| |
Collapse
|
16
|
Manfrini N, Ricciardi S, Miluzio A, Fedeli M, Scagliola A, Gallo S, Adler T, Busch DH, Gailus-Durner V, Fuchs H, de Angelis MH, Biffo S. Data on the effects of eIF6 downmodulation on the proportions of innate and adaptive immune system cell subpopulations and on thymocyte maturation. Data Brief 2017; 14:653-658. [PMID: 28924581 PMCID: PMC5591389 DOI: 10.1016/j.dib.2017.08.023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2017] [Revised: 08/02/2017] [Accepted: 08/24/2017] [Indexed: 11/28/2022] Open
Abstract
The data described in this article are related to “High levels of eukaryotic Initiation Factor 6 (eIF6) are required for immune system homeostasis and for steering the glycolytic flux of TCR-stimulated CD4+ T cells in both mice and humans” (Manfrini et al., in press) [1]. eIF6 is a translation initiation factor required for ribosomal biogenesis (Sanvito et al., 1999) [2] and for proper translational initiation (Gallo and Manfrini, 2015; Miluzio et al., 2016) [3], [4] whose protein abundance requires tight regulation. Here we analyze by flow cytometry the effects of eIF6 depletion on proportions of specific innate and adaptive immune system subpopulations and on thymocyte maturation in mice.
Collapse
Affiliation(s)
- Nicola Manfrini
- National Institute of Molecular Genetics "Romeo ed Enrica Invernizzi" - INGM, via F. Sforza 35, 20122 Milan, Italy
| | - Sara Ricciardi
- National Institute of Molecular Genetics "Romeo ed Enrica Invernizzi" - INGM, via F. Sforza 35, 20122 Milan, Italy
| | - Annarita Miluzio
- National Institute of Molecular Genetics "Romeo ed Enrica Invernizzi" - INGM, via F. Sforza 35, 20122 Milan, Italy
| | - Maya Fedeli
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, DIBIT, H. San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy
| | - Alessandra Scagliola
- National Institute of Molecular Genetics "Romeo ed Enrica Invernizzi" - INGM, via F. Sforza 35, 20122 Milan, Italy.,Department of Biosciences, University of Milan, Via Celoria 26, 20133 Milan, Italy
| | - Simone Gallo
- National Institute of Molecular Genetics "Romeo ed Enrica Invernizzi" - INGM, via F. Sforza 35, 20122 Milan, Italy.,Department of Biosciences, University of Milan, Via Celoria 26, 20133 Milan, Italy
| | - Thure Adler
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany
| | - Dirk H Busch
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Trogerstrasse 30, 81675 Munich, Germany
| | - Valerie Gailus-Durner
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany
| | - Helmut Fuchs
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany
| | - Martin Hrabě de Angelis
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany.,Center of Life and Food Sciences Weihenstephan, Technische Universität München, 85354 Freising, Germany.,German Center for Diabetes Research, 85764 Neuherberg, Germany
| | - Stefano Biffo
- National Institute of Molecular Genetics "Romeo ed Enrica Invernizzi" - INGM, via F. Sforza 35, 20122 Milan, Italy.,Department of Biosciences, University of Milan, Via Celoria 26, 20133 Milan, Italy
| |
Collapse
|